Although much attention has focused lately on vaccines to prevent SARS-CoV-2 infection, Eli Lilly and Company’s drug bamlanivimab may have a future as a way to prevent outbreaks in long-term care facilities, based on data from a Phase III study.
The Indianapolis-based drug maker said on 21 January that in the BLAZE-2 study, bamlanivimab reduced the risk of contracting COVID-19...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
